By inclusion on the statutory list of medicinal products, Efemia bladder support will be listed to the pharmacies in Germany as an aid eligible for reimbursement, according to the Aids Directive of the Federal Joint Committee.

- We are in active discussions with major health insurance companies such as AOK Rheinland, says director of Arteriomed Helga Wachtmeister. Once Arteriomed has finalized the discussions with the relevant insurance companies, the women in Germany should get a broader access to Efemia. Once these discussions are completed, we will know the level of reimbursement, she adds.

- I am thrilled that we, after almost a year of discussions with the authorities, have come this far in getting Efemia bladder support available for reimbursement in Germany, says the CEO of Invent Medic Karin Bryder.

This disclosure contains information that Invent Medic Sweden is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 04-10-2020 20:39 CET.

For more information please contact
Karin Bryder, CEO
Phone: +46 (0)723811710
E-mail: info@inventmedic.com

About Invent Medic
Invent Medic Sweden AB (Invent Medic) is a Swedish company developing innovative products with the aim to improve women’s health and quality of life. The company’s products are to be safe, effective and easy to use. Invent Medic’s first product, Efemia, is a CE-certified and patented medical technology product used to reduce stress urinary incontinence (SUI) that was shown to reduce urine leakage with 77 percent during usage in a clinical study. The product is based on the same scientific principle as the TVT method, the premier surgical treatment for SUI. Invent Medic’s share is listed on the Spotlight Stock Market with the ticker symbol IMS, and the share’s ISIN code is SE0007603402. More information can be found at www.inventmedic.com and www.spotlightstockmarket.com.